Início › Câncer de Próstata › Tennessee
Ensaios clínicos de Câncer de Próstata em Tennessee
49 estudos para Câncer de Próstata estão buscando participantes em locais em Tennessee.
Cidades em Tennessee
Texto oficial do estudo (Inglês)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Sarah Cannon Research Institute, Nashville
RecrutandoFase 1/2
Idades 12 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT04585750A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Sarah Cannon Research Institute, Nashville
- Tennessee Oncology PLLC, Nashville
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT06465069A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- SCRI Oncology Partners, Nashville
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT06172478Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Vanderbilt University/Ingram Cancer Center, Nashville
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 30 de set. de 2026 · NCT03866382A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
- Tennessee Oncology, Nashville
RecrutandoFase 1
Idades 18 e acima · Homens · Atualizado em 28 de set. de 2026 · NCT06095089DESTINY-PANTUMOUR04
- Research Site, Nashville
RecrutandoEstudo observacional
Idades de 18 a 130 · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT07124000A Study of JNJ-101556143 in Participants With Metastatic Prostate Cancer
- The Conrad Pearson Clinic, Germantown
RecrutandoFase 2
Idades 18 e acima · Homens · Atualizado em 25 de set. de 2026 · NCT07832292Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
- Sarah Cannon Research Institute, Nashville
- Urology Associates, Nashville
RecrutandoFase 1/2
Idades 18 e acima · Homens · Atualizado em 25 de set. de 2026 · NCT06800313A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
- The West Clinic, PLLC dba West Cancer Center ( Site 0063), Germantown
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06136650This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
- Tennessee Oncology, PLLC - Chattanooga Downtown, Chattanooga
- Tennessee Oncology PLLC, Chattanooga
- Tennessee Oncology, PLLC - Chattanooga Med Park II, Chattanooga
- e mais 20
RecrutandoFase 3
Idades 18 e acima · Homens · Atualizado em 24 de set. de 2026 · NCT07028853A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
- Tennessee Oncology, Nashville
RecrutandoFase 1
Idades 18 e acima · Homens · Atualizado em 24 de set. de 2026 · NCT07719361A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
- Sarah Cannon Research Institute Oncology Partners, Nashville
- United States Oncology Regulatory Affairs Corporate Office, Nashville
RecrutandoFase 3
Idades 18 e acima · Homens · Atualizado em 22 de set. de 2026 · NCT07213674Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
- Tennessee Oncology PLLC, Chattanooga
RecrutandoFase 3
Idades de 18 a 100 · Homens · Atualizado em 22 de set. de 2026 · NCT06855277A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
- Research Site, Nashville
RecrutandoFase 3
Idades 18 e acima · Homens · Atualizado em 18 de set. de 2026 · NCT06952803A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
- GSK Investigational Site, Nashville
RecrutandoFase 1/2
Idades 18 e acima · Homens · Atualizado em 18 de set. de 2026 · NCT06990880High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
- Memphis VA Medical Center, Memphis, TN, Memphis
- Tennessee Valley Healthcare System Nashville Campus, Nashville, TN, Nashville
RecrutandoFase 2
Idades 18 e acima · Homens · Atualizado em 17 de set. de 2026 · NCT05011383Phase 1 Trial to Study JANX013 and JANX007 Combination in mCRPC
- Sarah Cannon Research Institute, Nashville
RecrutandoFase 1
Idades 18 e acima · Homens · Atualizado em 17 de set. de 2026 · NCT07813637A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
- Memphis VA Medical Center ( Site 0072), Memphis
- SCRI Oncology Partners ( Site 0074), Nashville
- Henry-Joyce Cancer Clinic ( Site 0042), Nashville
RecrutandoFase 3
Idades 18 e acima · Homens · Atualizado em 17 de set. de 2026 · NCT06925737Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer
- Sarah Cannon Research Institute Oncology Partners, Nashville
RecrutandoFase 1
Idades 18 e acima · Homens · Atualizado em 15 de set. de 2026 · NCT07493512Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
- Urology Associates of Nashville, Nashville
RecrutandoFase 3
Idades 18 e acima · Homens · Atualizado em 11 de set. de 2026 · NCT06056830A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
- Sarah Cannon Research Center, Nashville
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 9 de set. de 2026 · NCT06440005A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer
- Sarah Cannon Research Institute, Nashville
RecrutandoFase 1/2
Idades 18 e acima · Homens · Atualizado em 4 de set. de 2026 · NCT07567846Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer
- SCRI Oncology Partners, Nashville
RecrutandoFase 1
Idades 18 e acima · Homens · Atualizado em 3 de set. de 2026 · NCT07545811A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
- Tennessee Oncology Nashville, Nashville
RecrutandoFase 2
Idades 18 e acima · Homens · Atualizado em 3 de set. de 2026 · NCT07005154AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
- Research Site, Nashville
RecrutandoFase 3
Idades 18 e acima · Homens · Atualizado em 26 de ago. de 2026 · NCT07611110Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
- Sarah Cannon Research Institute, Nashville
RecrutandoFase 2
Idades 18 e acima · Homens · Atualizado em 24 de ago. de 2026 · NCT07745361Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
- United States Oncology Regulatory Affairs Corporate Office, Nashville
RecrutandoFase 1
Idades 18 e acima · Homens · Atualizado em 21 de ago. de 2026 · NCT04221542A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Henry-Joyce Cancer Clinic, Nashville
RecrutandoFase 2
Idades 18 e acima · Homens · Atualizado em 17 de ago. de 2026 · NCT06842498FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Sarah Cannon Research Institute, Nashville
- Vanderbilt Ingram Cancer Center, Nashville
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 17 de ago. de 2026 · NCT05919264Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
- Sarah Cannon Research, Nashville
RecrutandoFase 1
Idades de 18 a 100 · Homens · Atualizado em 13 de ago. de 2026 · NCT05519449Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
- Tennessee Oncology PLLC, Nashville
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 30 de jul. de 2026 · NCT07288359Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
- Investigative Site #102, Nashville
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 23 de jul. de 2026 · NCT06545942PSMA PET Combined With MRI for the Detection of PCa
- The Conrad Pearson Clinic, Germantown
- Urology Associates of Nashville, Nashville
RecrutandoFase 3Voluntários saudáveis bem-vindos
Idades 18 e acima · Homens · Atualizado em 23 de jul. de 2026 · NCT07052214Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
- Vanderbilt University/Ingram Cancer Center, Nashville
RecrutandoFase 3
Idades 18 e acima · Homens · Atualizado em 14 de jul. de 2026 · NCT06592924Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
- Sarah Cannon Research Institute, Nashville
RecrutandoFase 1
Idades 18 e acima · Homens · Atualizado em 2 de jul. de 2026 · NCT07140900International Registry for Men With Advanced Prostate Cancer (IRONMAN)
- Memphis VA Medical Center, Memphis
- Baptist Clinical Research Institute, Memphis
RecrutandoEstudo observacional
Idades 21 e acima · Homens · Atualizado em 22 de mai. de 2026 · NCT03151629Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
- Sarah Cannon Research Institute, Nashville
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 6 de mai. de 2026 · NCT06239194A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
- Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville
- Vanderbilt University Medical Center, Nashville
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 13 de fev. de 2026 · NCT06778863A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
- Urology Associates PC, Nashville
RecrutandoFase 1
Idades 18 e acima · Homens · Atualizado em 4 de fev. de 2026 · NCT04729114Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
- The West Clinic - Wolf River, Germantown
RecrutandoFase 3
Idades 18 e acima · Homens · Atualizado em 22 de jan. de 2026 · NCT06470243Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.